AZN Share PerformanceMore
|52 week high||5,520 22/06/17|
|52 week low||3,996 06/12/16|
|52 week change||208 (4.20%)|
|4 week volume||42,364,590 20/09/17|
Latest News« previous» nextMore
16/10/2017 - 12:50 StockMarketWire
Credit Suisse today upgrades its investment rating on AstraZeneca PLC (LON:AZN) to outperform (from neutral) and rai...
16/10/2017 - 09:30 StockMarketWire
Jefferies International today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and raised its price tar...
11/10/2017 - 11:37 Interactive Investor
If hedge funds smell blood they'll attack vulnerable companies for profit. David Brenchley reveals this fund's short positio...
09/10/2017 - 08:10 StockMarketWire
HSBC today reaffirms its reduce investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 4150p (f...
09/10/2017 - 07:19 StockMarketWire
AstraZeneca has announced that the US Food and Drug Administration has granted breakthrough therapy designation fo...
09/10/2017 - 07:00 RNS
RNS Number: 0020T AstraZeneca PLC 09 October 2017 9 October 2017 07:00 BST TAGRISSO GRANTED BREAKTHROUGH THERAPY DESIGNATION BY US FDA FOR THE 1ST-LINE TREATMENT OF PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER Designation based on positive Phase III FLAURA trial results Sixth...
02/10/2017 - 15:00 RNS
RNS Number: 4425S AstraZeneca PLC 02 October 2017 02 October 2017 15:00 BST Transparency Directive Voting Rights and Capital The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 September 2017 the issued share capital of AstraZeneca PLC with voting rights is 1,265,913,842...
26/09/2017 - 12:00 RNS
RNS Number: 8473R AstraZeneca PLC 26 September 2017 26 September 2017 12:00 BST TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES Disclosure under Article 19 of the EU Market Abuse Regulation AstraZeneca PLC (the Company) announces that, on 25 September 2017, an award of the Company's American Depositary Shar...
Latest discussion posts More
“The European Medicines Agency accepts for review AstraZeneca's (NYSE:AZN) marketing application seeking approval for Imfinzi (durvalumab) for the treatment of patients with ...”▼
“AstraZeneca has announced that the US Food and Drug Administration has granted breakthrough therapy designation for Tagrisso (osimertinib) for the first-line treatment of ...”▼
“up another 10+%”▼
Codes & Symbols
|Symbols||AZN, LSE:AZN, AZN.L, AZN:LN, LON:AZN, XLON:AZN|